We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Spectrum Pharmaceuticals Appoints COO
News

Spectrum Pharmaceuticals Appoints COO

Spectrum Pharmaceuticals Appoints COO
News

Spectrum Pharmaceuticals Appoints COO

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Spectrum Pharmaceuticals Appoints COO"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Mr Keller has more than twenty years experience in the pharmaceutical industry ranging from Sales and Marketing Leadership, General Management and Joint Venture Leadership in several therapeutic areas, including Oncology, Rheumatology, Dermatology and Primary Care.

"We are pleased to welcome Ken to Spectrum and believe he will be a strong asset to our management team," stated Rajesh C. Shrotriya, M.D., Chairman, President and Chief Executive Officer of Spectrum Pharmaceuticals, Inc. "Ken is a leader in marketing and product launches, having directed the commercialization programs for three of Amgen's top five biologics in worldwide sales. As Spectrum prepares for increased sales of its current product portfolio and introductions of new products, we anticipate Ken's experience will be invaluable."

"I am excited to join Spectrum because the company has spectacular growth prospects. With FUSILEV, FOLOTYN and ZEVALIN, a rapidly advancing pipeline of ten drugs in development and outstanding financial strength, Spectrum is in a unique position to quickly become a leading biopharmaceutical company. The progress over the past decade has been remarkable, a solid foundation has been established and all the pieces are in place to significantly accelerate growth. I'm looking forward to helping Spectrum become the next great growth story in the biopharmaceutical industry," stated Ken Keller, Executive Vice President, Chief Operating Officer of Spectrum Pharmaceuticals, Inc.

Prior to joining Spectrum, Mr. Keller spent 21 years at Amgen. His most recent role was Vice President and General Manager, Bone Health Business Unit. Previous to this role he was responsible for the Inflammation Business Unit which contributed over $3 billion in revenue. During his career at Amgen, Mr. Keller has been the Marketing Lead or the General Manager for four of the world's top selling biologic medicines Neupogen®, Neulasta®, Aranesp® and Enbrel®. He also has significant international experience, as Managing Director for Amgen's United Kingdom and Ireland Affiliate.

Mr. Keller holds a Bachelors of Science degree in Business from Saint Johns University and a Masters in Business Administration from Loyola Marymount University.

Advertisement